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IL-12 Controls Cytotoxicity of a Novel Subset of
Self-Antigen-Specific Human CD28 Cytolytic T Cells1
Catherine Barbey,2* Petra Baumgaertner,2* Estelle Devevre,* Verena Rubio-Godoy,*
Laurent Derre,* Gabriel Bricard,* Philippe Guillaume,† Immanuel F. Luescher,†
Danielle Lie´nard,* Jean-Charles Cerottini,*† Pedro Romero,*§ Nathalie Rufer,2‡§
and Daniel E. Speiser2,3*§
Activated CD8 T cells develop cytotoxicity against autologous cells bearing foreign Ags and self/tumor Ags. However, self-specific
cytolysis needs to be kept under control to avoid overwhelming immunopathology. After peptide vaccination of melanoma patients,
we studied molecular and functional properties of T cell subsets specific for the self/tumor Ag Melan-A/MART-1. Ex vivo analysis
revealed three Ag-specific effector memory (EM) populations, as follows: CD28-negative EM (EM28) T cells strongly expressing
granzyme/perforin, and two EM28 subsets, one with high and the other with low level expression of these cytotoxic proteins. For
further functional characterization, we generated 117 stable CD8 T cell clones by ex vivo flow cytometry-based sorting of these
subsets. All EM28-derived clones lysed target cells with high efficacy. In contrast, EM28-derived clones were heterogenous, and
could be classified in two groups, one with high and the other with low killing capacity, correlating with granzyme/perforin
expression. High and low killer phenotypes remained surprisingly stable for several months. However, strongly increased gran-
zyme expression and cytotoxicity were observed after exposure to IL-12. Thus, the data reveal a newly identified subset of CD28
conditional killer T cells. Because CD28 can mediate strong costimulatory signals, tight cytotoxicity control, as shown in this study
through IL-12, may be particularly important for subsets of T cells expressing CD28. The Journal of Immunology, 2007, 178:
3566–3574.
I n response to antigenic challenge, T cells undergo complexprograms of differentiation, which are still only partially de-fined. A better understanding of the regulation of T cell dif-
ferentiation and function will most likely provide new perspectives
for therapeutic interventions. To enhance immune protection
against infection and cancer, improved therapies need to promote
more robust (and longer lasting) T cell responses. Conversely, bet-
ter control of transplant rejection and autoimmune disease depends
on novel therapeutic interventions that block T cells efficiently. In
any case, more potent therapies are also associated with increased
risks (1–3), emphasizing the need for detailed knowledge of con-
trol mechanisms.
Immune activation induces multiple subsets of Ag-specific T
cells with distinct properties (4–8). Despite specialization, many T
cells remain receptive to environmental signals, allowing changes
in differentiation and functional status. Some T cells develop ef-
fector functions, whereas others specialize for high proliferative
potential, often essential for protective immune responses and im-
munological memory (9–11).
Human CD8 T cell responses against tumor Ags and persistent
viruses are usually dominated by CCR7/CD45RA effector
memory (EM)4 T cells. They are heterogenous, and contain sub-
sets expressing various cytokines and/or cytolytic proteins such as
granzymes and perforin (12–14). Whereas proliferating T cells
continue to express CD28 and CD27, a large proportion of effector
T cells down-regulates these costimulatory molecules (15, 16). In-
deed, the majority of virus- and tumor-specific CD8 effector T
cells are CD27 and CD28 negative, correlating with enhanced
expression of effector proteins (cytokines, cytolytic proteins, NK
receptors) (12–20).
Costimulation through CD28 strongly supports T cell activation
(21). Nevertheless, a large fraction of human CD8 T cells does not
express CD28. During recent years, it became increasingly clear
that the pool of CD28-negative T cells primarily represents clas-
sical CD8 T cells with specificities against non-self and self Ags,
similar to their CD28-positive counterparts (16, 18, 22). Indeed,
specific clonotypes can often be observed in both CD28-positive
and CD28-negative pools (our unpublished data). The latter can
exert strong effector function despite that they lack CD28 ex-
pression. Based on current evidence, it seems likely that CD28
down-regulation represents a major control mechanism to avoid
overwhelming T cell activation and immunopathology. CD28
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down-regulation appears to be the result of extended and pro-
longed T cell stimulation. Typically, this condition is also as-
sociated with immune attenuation controlled through multiple
mechanisms (23–29).
A recent human trial unexpectedly revealed strong unfavorable
side effects caused by small doses of an activatory CD28-specific
Ab (1, 2), emphasizing the need for more detailed characterization
of mechanisms controlling human CD28 T cells. In this study,
we investigated the heterogeneity of Ag-specific EM CD8 T cells
after peptide vaccination of melanoma patients. Ex vivo anal-
ysis revealed three Melan-A/MART-1-specific populations, as
follows: CD28-negative EM (EM28) T cells strongly express-
ing granzyme/perforin, and two EM28 subsets, one with high
and the other with low level expression of these cytotoxic pro-
teins. For further functional characterization, we generated 117
stable CD8 T cell clones by ex vivo flow cytometry-based sort-
ing of these subsets. EM28-derived clones efficiently killed
specific target cells. In contrast, a large fraction of EM28-
derived clones was unable to kill, correlating with poor gran-
zyme/perforin expression. High and low killer phenotypes re-
mained surprisingly stable, and correlated well with the results
from ex vivo studies. However, strongly increased granzyme
expression and cytotoxicity were observed after exposure to
IL-12. Together, the data reveal the existence of a conditional
killer subset of self Ag-specific T cells, controlled by IL-12,
representing a novel checkpoint restricting cytotoxicity in
humans.
Materials and Methods
Patients and peptide vaccination
As described previously (30), HLA-A*0201-positive patients with histo-
logically proven metastatic melanoma of the skin expressing Melan-A/
MART-1 (RT-PCR or immunohistochemistry) were vaccinated in monthly
intervals. Vaccines were injected s.c. and contained 500 g of CpG oligode-
oxynucleotide 7909 (provided by A. Krieg Coley Pharmaceutical Group,
Wellesley, MA), 100 g of Melan-A analog peptide26–35 ELAGIGILTV
(Ludwig Institute for Cancer Research), and 300 l of Montanide
ISA-51 (IFA; Seppic), mixed altogether and prepared in a syringe as a
stable emulsion.
Blood cells, HLA-A2/peptide multimers, and flow cytometry
Blood was withdrawn from patients 7–10 days after booster vaccination. Fi-
coll-Paque-centrifuged PBMC (1  107) were cryopreserved in RPMI 1640,
40% FCS, and 10% DMSO. PE-labeled HLA-A*0201/ELAGIGILTV peptide
multimers (originally called tetramers) were prepared, as described (31, 32).
Anti-CD8, anti-CD28, and goat anti-rat IgGAPC were purchased from BD Bio-
sciences. Five color stains were done with HLA-A2/peptide multimers, anti-
CD28FITC, anti-CD45RAPE-Texa Red (Beckman Coulter), anti-CD8APC-Cy7 re-
agents, and anti-CCR7 mAb (from M. Lipp, Max Delbrueck-Center for
Molecular Medicine, Berlin, Germany), followed by goat anti-rat IgGAPC Ab.
Briefly, CD8 T cells were enriched using a MiniMACS device (Miltenyi
Biotec), resulting in 90% CD3/CD8 cells. Cells (106) were incubated
with multimers (1 g/ml, 60 min, room temperature) and then with Abs (30
min, 4°C). Intracellular content of granzyme B and perforin was measured in
freshly isolated CD8 T cells without previous stimulation. In brief, after mAb
staining, cells were fixed for 20 min at room temperature in PBS containing
1% formaldehyde, 2% glucose, and 5 mM sodium azide. Fixation and per-
meabilization were done with PBS, saponin (0.1%; Fluka), BSA (0.2%), and
EDTA (50 M), followed by staining with granzyme BFITC (Hoelzel Diag-
nostika) or perforinFITC mAbs (Alexis) for 20 min at room temperature.
Fluorescent isotype-matched Abs with irrelevant specificity were used
as negative controls. A total of 5  105 CD8 T cells/sample was
acquired with a FACSVantage SE machine, and data were analyzed
with CellQuest software (BD Biosciences).
T cell sorting, cloning, and cytotoxicity assays
CD8 T cells from uncultured PBMC were prepared and stained with
multimers and Abs, as described above. Subsequently, the multimer
CD8 T cell subsets were sorted by flow cytometry, cloned in Terasaki
plates at 0.3 cell/well, and expanded with PHA and allogenic feeder cells
in RPMI 1640 medium supplemented with nonessential amino acids,
sodium pyruvate, penicillin-streptomycin, kanamycine, 2-ME, 5% hu-
man serum, and 150 U/ml rIL-2. Subsequently, they were periodically
(3– 4 wk) restimulated with PHA, irradiated feeder cells, and rIL-2.
Lytic activity and Ag recognition were assessed in 4-h 51Cr release
assays, using ELAGIGILTV (Melan-A26.35 analog) as peptide (32, 33)
and T2 target cells (A*0201/Melan-A). The redirected lysis assay
was done with FcR-expressing P815 mastocytoma target cells and
anti-CD3 OKT3 mAb (34). The percentage of specific lysis was calcu-
lated as follows: 100  ((experimental  spontaneous release)/(total 
spontaneous release)). Cultures with rIL-12 (5 ng/ml; R&D Systems)
were done with clones in absence of feeder cells, or with PBMC from
healthy donors, in 5% human serum and 150 U/ml rIL-2. After 6, 24,
48, and 72 h of culture, cells were stained with anti-CD3 and anti-CD8
Abs, permeabilized, stained with Abs specific for granzyme B or per-
forin, and analyzed by gating on CD3CD8 cells.
Cytokine production
CCR7/CD45RA, EM28, and EM28 ex vivo derived T cell clones
(3  105 cells) were stimulated with 3  105 irradiated T2 target cells, in
the presence or absence of Melan-A peptide (1 g/ml), in a total volume
FIGURE 1. CD8 T cells responding to peptide vaccination are pre-
dominantly CCR7/CD45RA, with subsets distinguished by expres-
sion of CD28, granzyme B, and perforin. A, High frequencies of ex vivo
detectable circulating CD8 Melan-A-specific T cells after vaccination
with low doses of CpG 7909, Melan-A peptide, and IFA. In the three
patients, LAU 371, LAU 444, and LAU 944, Melan-A multimer T
cells were found at 2.08, 3.00, and 1.25% of CD8 T cells, respectively
(gate R1; A). These cells were dominantly CCR7/CD45RA EM cells
(30). Gating on EM cells showed that a fraction of these cells was CD28
positive, whereas the remaining were CD28 negative. B, Costaining
with granzyme B and perforin-specific Abs revealed bimodal distribu-
tions, with large fractions of granzyme B and perforin-negative cells in
total CD8 T cells and EM28, but not EM28 cells. PBMC were col-
lected 7–10 days after vaccination, and analyzed ex vivo by multipa-
rameter flow cytometry upon staining with A2/Melan-A multimers and
Abs specific for CD8, CD45RA, CCR7, CD28, granzyme B, and per-
forin. Part of the data has been reported previously (30).
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of 1 ml. After 40 h, supernatants were collected and cytokine content was
determined by FACS analysis with a CBA kit from BD Biosciences, ac-
cording to the manufacturer’s instructions.
Results
High percentages of Melan-A-specific EM (CCR7/CD45RA)
T cells after peptide vaccination
As reported previously (30), we observed strongly increased fre-
quencies of circulating Melan-A-specific T cells (Fig. 1A) after
vaccination of advanced stage III/IV melanoma patients with low
dose Melan-A/MART-1 peptide, CpG oligodeoxynucleotide 7909,
and IFA. Between 1.25 and 3.00% of circulating CD8 T cells were
positive when stained with HLA-A*0201/Melan-A multimers, as
shown in Fig. 1A for the three patients (LAU 371, LAU 444, and
LAU 944) analyzed in depth in the present study. The vast ma-
jority of Ag-specific T cells were negative for CCR7 and
CD45RA, so-called EM cells (13, 30). These dominant EM cells
were in part CD28 positive (EM28) and in part CD28 negative
(EM28). Although the proportions of EM28 and EM28 cells
varied between the three patients, both populations were present in
all three patients (Fig. 1A).
Differences in granzyme B and perforin expression between
EM28 and EM28 Melan-A-specific T cells
To determine the expression of effector proteins in vivo, we com-
bined surface and intracellular staining. Gating on total CD8 T
cells showed bimodal distributions, with fractions of cells express-
ing granzyme B and perforin in each patient (Fig. 1B). We also
found bimodal distributions when gating on EM28 cells, as fol-
lows: T cells from the three patients expressed granzyme B at
frequencies of 37, 15, and 54%, and perforin was expressed at 31,
17, and 44% (Fig. 1B). By sharp contrast, EM28 cells were pre-
dominantly positive for granzyme B and perforin. Thus, most
EM28 T cells expressed cytolytic effector proteins, in contrast to
EM28 T cells, which contained a substantial fraction of cells
lacking such proteins in each patient.
A significant fraction of T cell clones derived from CD28 EM
cells exhibits poor cytolytic activity
For functional analysis, we generated a total of 117 stable T cell
clones from PBMC of the three patients, through FACS sorting
of CD8 multimer T cells gated according to expression of
CCR7, CD45RA, and CD28. Individually sorted T cells were
put in culture and stimulated with PHA and allogenic feeder
cells to obtain T cell clones sorted ex vivo from the prominent
CCR7/CD45RA EM subpopulations, as follows: 48 clones
were derived from EM28 cells, and 39 from EM28 cells. As
controls, we also generated 30 clones derived from putatively
naive CCR7/CD45RA cells (35). All 117 clones were tested
in cytotoxicity assays to measure percent specific lysis in rela-
tion to Melan-A peptide concentration used for target cell load-
ing (Fig. 2). EM28-derived clones strongly killed peptide-
loaded T2 cells, revealing a remarkable functional homogeneity
(Fig. 2A). In contrast, cytotoxicity was heterogenous in the two
other groups of clones, with a surprising absence or poor killing
(25% specific lysis at high peptide concentrations) in a sub-
stantial fraction of EM28-derived clones, and some CCR7/
CD45RA-derived clones (Fig. 2A). To examine whether poor
killing was due to insufficient TCR triggering by MHC/peptide,
we performed redirected lysis assays, using anti-CD3 Abs that
bind to P815 target cells via FcR mediating efficient T cell/
target cell interaction. Nevertheless, there was still a large frac-
tion of EM28-derived clones showing no or poor killing of
P815 cells (Fig. 2B). Thus, in contrast to EM28-derived
clones, many EM28-derived clones were poorly cytotoxic,
even under conditions of strong T cell/target cell cross-linking.
FIGURE 2. Differential cytotoxicity of T cell clones
depending on in vivo differentiation stage. From circulat-
ing CD8 T cells of the three patients, 117 T cell clones
were generated through ex vivo flow cytometric sorting,
by gating on T cell subpopulations with distinct pheno-
types. A, The six graphs on the top show representative
cytotoxicity results of 3  2 individual clones derived
from CCR7/CD45RA, EM28, and EM28 subsets,
respectively, using T2 target cells in presence of titrated
Melan-A peptide. The three figures below show for each
of the three family of clones the percentage of maximal
lysis (y-axis) and the concentration of peptide required for
50% maximal lysis (x-axis). Each data point represents the
result from an individual clone. Clones with 25% max-
imal lysis/total number of clones tested are as follows: 5 of
30 CCR7/CD45RA-derived clones, 20 of 48 EM28-
derived clones, and 0 of 39 EM28-derived clones. B, In
parallel, redirected (i.e., anti-CD3 mAb-directed) cytotox-
icity was measured against P815 target cells. Upper panel,
Shows anti-CD3 mAb titration experiments with the same
representative clones as in A. The lower three figures show
maximal lysis (y-axis) of each clone, in relation to the con-
centration of cross-linking anti-CD3 mAb needed for 50%
maximal lysis (x-axis). Clones with 25% maximal lysis/
total number of clones tested are as follows: 0 of 12 for
CCR7/CD45RA-derived clones, 8 of 21 for EM28-
derived clones, and 0 of 15 for EM28-derived clones.
Clones with 0% cytotoxic activity were grouped and sym-
bolized as a single dot on the right end of the x-axis, to
visualize them in the figures, despite that peptide/Ab con-
centrations for half-maximal lysis could not be determined.
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The peptide titration experiments (Fig. 2A) show that EM28-
derived clones required only low peptide concentrations for
half-maximal lysis of T2 cells (mean concentration between
0.01 and 0.1 nM). In contrast, CCR7/CD45RA- and EM28-
derived clones were more heterogenous, with the majority of
CCR7/CD45RA-derived clones requiring 1 nM, and many
of the EM28-derived clones 0.1 nM concentrations for half-
maximal lysis. Importantly, the three different T cell subpopu-
lations (CCR7/CD45RA, EM28, and EM28) were found
in three of three patients, and sorting and cloning from blood
samples obtained at multiple dates per patient reproducibly led
to the generation of the described clones with high and low
killing, indicating that these subpopulations coexist simulta-
neously in all three patients.
Low granzyme B and perforin expression in EM28-derived
clones correlating with low cytotoxicity
To investigate whether poor killing was due to deficiencies in
the expression of cytotoxic effector proteins, we performed in-
tracellular staining of granzyme B and perforin (Fig. 3A). All
EM28-derived clones expressed high levels of granzyme B.
CCR7/CD45RA-derived clones exhibited lower values, and
EM28-derived clones were in part very low and displayed a
substantial heterogeneity between clones. The overall staining
for perforin was lower, in part explained by the less efficient
staining obtained with this mAb as compared with the granzyme
B-specific mAb. Nevertheless, the pattern was comparable to
granzyme B: practically all EM28-derived clones were per-
forin positive, in contrast to EM28 and CCR7/CD45RA-
derived clones, which were partially perforin negative. The re-
sults correlated significantly with maximal cytotoxicity against
T2 cells loaded with saturating peptide doses (1 M; Fig. 2A),
because strongly granzyme B-positive cells lysed T2 cells more
efficiently than granzyme B low cells (Fig. 3B). A similar pat-
tern was observed for perforin expression (data not shown).
Together, the data demonstrate that all EM28-derived clones
expressed high levels of cytotoxic proteins and exerted strong
killing, and that CCR7/CD45RA-derived clones also killed
relatively well. In contrast, EM28-derived clones were heter-
ogenous with many that had poorly developed cytotoxic
capacity.
Long-term in vitro maintenance of phenotype and function of
T cell clones
The above described assessment of cytotoxicity was performed
between 2 and 5 mo after the generation of T cell clones,
whereby the clones were tested two to four times with intervals
of in part 3 mo of culture. As frequently observed, cytotoxic
activity was variable during the first 1–2 mo after cloning, and
varied depending on the number of days after restimulation of
clones (data not shown). Afterward, high or low killing became
remarkably stable features of individual clones. Under these
conditions, we also assessed CD28 expression in the clones
cultured for 2–5 mo (Fig. 3C). The CCR7/CD45RA-derived
clones were often CD28 positive or bimodal, i.e., they were
FIGURE 3. Differential expression of granzyme B and perforin among EM28 clones correlating with cytotoxicity. A, The three families of clones were
permeabilized and stained with mAbs specific for granzyme B (left) and perforin (right). Filled histograms: stainings with isotype-matched control Ab. B,
Maximal lysis of Melan-A peptide-loaded T2 cells (data from Fig. 2A) is plotted against mean fluorescence of granzyme B staining, revealing a
statistically significant correlation of cytotoxicity and granzyme B expression (p  0.001 for all clones, p  0.05 for EM28-derived clones, NS
for CCR7/CD45RA- and EM28-derived clones; ANOVA). C, Long-term maintenance of CD28 phenotype. T cell clones were stained with
CD28-specific mAbs. The histograms show results from three clones for each group, demonstrating that most EM28- and EM28-derived clones
expressed CD28 according to the ex vivo sorting that was initially performed for their generation. In contrast, CCR7/CD45RA-derived clones
were heterogenous. A summary of results for CD28 expression by clones derived from the three patients, LAU 371, LAU 444, and LAU 944, is
shown below the figure (clones expressing CD28/total clones).
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partially CD28 positive and partially CD28 negative. In con-
trast, the majority of clones originating from EM28 PBMC
expressed CD28, and clones from EM28 PBMC had no de-
tectable CD28 expression. Thus, CD28 phenotype and cytotoxic
function of EM-derived T cell clones remained stable, despite
that they were maintained in culture for several months.
Increased cytokine secretion by EM28-derived T cell clones
To assess the ability of the clones to produce cytokines, we
stimulated them with peptide-loaded T2 cells and measured cy-
tokines in culture supernatants. IFN- was well detectable in all
clones, with significantly higher levels of IFN- produced by
EM28 cells (Fig. 4). More significantly, as compared with
EM28- and CCR7/CD45RA-derived cells, EM28-derived
clones were superior in the production of IL-2, IL-4, IL-5, and
TNF-. Therefore, EM28 cells strongly secreted IL upon
short-term Ag stimulation. Cell viability was comparable in
EM28- and EM28-derived clones (data not shown), indicat-
ing that differential IL production was not due to differences in
cell survival. Among the six cytokines tested, only IL-10 was
not significantly increased in EM28-derived clones as com-
pared with the other populations. Finally, we addressed the
question whether among EM28-derived clones, cytokine se-
cretion would correlate inversely with killing. We found a trend
toward stronger cytokine release by those cells with poor killing
and low granzyme B expression. However, this was not statis-
tically significant for any of the six cytokines tested (data not
shown).
IL-12-induced granzyme B expression and cytotoxicity
To investigate whether T cells can acquire cytotoxic capacity,
we stimulated them for 6 h with PMA and ionomycin. However,
this did not up-regulate killing nor granzyme B/perforin expres-
sion (data not shown). A recent report indicated that murine
CD8 T cells require IL-12 for the development of cytotoxicity
(36). Therefore, we analyzed our T cell clones after incubation
in medium supplemented with IL-12 for 3 days, and compared
the results with clones that had been kept conventionally, i.e.,
similarly as for the experiments described above. Interestingly,
IL-12 led to increased cytotoxicity (Fig. 5A), which was par-
ticularly enhanced in clones with initially low cytotoxicity (Fig.
5B). In parallel, we observed a significantly increased expres-
sion of granzyme B (Fig. 5C). Clones with initially strong kill-
ing also showed some degree of IL-12-mediated up-regulation
of killing and granzyme B, which was, however, less pro-
nounced than in clones with initially low cytotoxicity (Fig. 5, B
and C). In contrast, we observed similar levels of perforin ex-
pression in presence and absence of IL-12. Kinetic studies
showed that IL-12-driven granzyme B up-regulation was al-
ready detectable at 24 h and became strong at 48 h (Fig. 5D).
Subsequently, we analyzed CD8CD3 PBMC of healthy do-
nors, and again found IL-12-mediated up-regulation of gran-
zyme B, but not perforin (Fig. 5E). This up-regulation was,
however, weaker and slower (Fig. 5F) as opposed to clones,
because the differences were smaller and became statistically
significant only after 72 h (Fig. 5D). Together, the data dem-
onstrate IL-12-driven up-regulation of granzyme B in CD8 T
cells from circulating blood and in conditional killer clones.
Finally, we determined whether IL-12 would also increase IFN-
production by Ag-stimulated T cell clones cultured for 24 and
72 h. However, neither intracellular IFN- content nor the amount
of IFN- secreted in culture supernatants was increased in cultures
with vs without IL-12 (data not shown).
FIGURE 4. Cytokine secretion by T cell clones.
Clones were stimulated with peptide-loaded T2 cells,
and cytokine secretion was quantified with cytokine
bead arrays. A, Concentration of cytokines secreted by
individual CCR7/CD45RA, EM28, and EM28 T
cell clones. Numbers of clones tested were 12, 31, and
24, respectively. B, Cytokine secretion comparison be-
tween T cell clones derived from CCR7/CD45RA
(), EM28 (f), and EM28 (bars with horizontal
lines) cells. Data represent means and SD. Only statis-
tically significant differences between groups are de-
picted. , p  0.05; , p  0.01; , p  0.001
(ANOVA, Student’s t test).
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Discussion
We analyzed subsets of human Ag-specific CD8 T cells, and de-
termined functional differences in CD28-negative and CD28-pos-
itive EM cells. We found that the latter were composed of two
subsets, one with high and the other with low cytotoxicity, corre-
lating with their levels of granzyme B and perforin expression.
Targeted cell sorting, followed by the generation of representative
clones, revealed impressive stability of phenotypes, and poor cy-
totoxic potential in cells with low level expression of granzyme B.
However, exposure to IL-12 led to strong up-regulation of gran-
zyme B and cytolysis in these conditional killer T cells.
To assess the functional status of T cells, we primarily and sys-
tematically focused on expression of granzyme B and perforin
(Figs. 1, 3, and 5). In addition, cytotoxicity was measured when-
ever possible (Figs. 2, 3, and 5). The fact that cytotoxicity corre-
lated well with expression levels of granzyme B (Figs. 3 and 5)
allowed us to draw conclusions about the in vivo status, despite
that ex vivo functional testing for cytotoxicity of individual cells is
not possible with currently available techniques. Recently, we
have developed a novel assay for ex vivo measurements of cyto-
toxicity by small numbers of Ag-specific T cells (37). However, in
most instances, it still remains impossible to perform ex vivo func-
tional cytotoxicity tests with subsets of multimer T cells. Nev-
ertheless, we could test total Melan-A multimer T cells from two
patients (LAU 371 and LAU 944), and found that both reached
90–100% specific lysis of peptide-labeled T2 cells at E:T ratios
4. Interestingly, maximally reached levels of CD107a were
much higher in patient LAU 944 (56%) than in patient LAU 371
(23%; data not shown), revealing a considerable difference of the
fraction of lytic cells, and confirming the finding in this study that
patient LAU 371 had many more nonlytic T cells than patient
LAU 944.
Our results reveal a new mechanism for regulation of cytotox-
icity in human CD8 T cells. Recent results in mice demonstrated
that IL-12 (36, 38) and type I IFN (39, 40) play major roles in the
control of T cell cytotoxicity. Interestingly, lytic and nonlytic mu-
rine T cells were similar in conjugate formation with Ag-bearing
target cells, Ag-dependent calcium flux, and degranulation in re-
sponse to TCR signaling. The only parameter significantly corre-
lating with lytic activity was granzyme B content, which was much
higher in T cells exposed to IL-12 (41), similar to our observations.
We also cultured T cell clones in presence of IFN-, which did,
however, not result in up-regulation of granzyme B and cytotox-
icity (data not shown). At least three explanations may account for
this, as follows: 1) additional signals to IFN- may be required to
induce cytotoxicity; 2) cytotoxicity of human T cell subsets other
than the ones studied in this work may depend on IFN-; or 3)
IFN- does not play this role in humans as it does in mice (39, 40).
Costimulation through CD28 leads to strong T cell activation
(21), and can cause dramatic side effects particularly in humans (1,
2). T cell effector function, especially cytotoxicity, must be tightly
controlled to avoid harmful extended cytotoxicity. As compared
FIGURE 5. Induction of granzyme B expression and cytolysis by IL-12. A, Two conditional killer clones (clones 23 and F3) and one cytotoxic clone
(clone 95.2) were analyzed in 4-h 51Cr release assays, after 3-day culture in IL-2-containing medium as usual, in absence (left) or presence (right) of IL-12
(5 ng/ml). Target cells were T2 cells without peptide (open symbols) or loaded with Melan-A analog peptide (closed symbols). B, The ratio of maximal
lysis with/without IL-12 incubation was calculated; compiled results from seven and four clones (with high and low initial cytotoxicity,  and f,
respectively) are shown. C, In parallel to cytotoxicity assays, clones were permeabilized and stained with Abs specific for granzyme B (left) and perforin
(right); results from clones after incubation with IL-12 (filled histograms) and without IL-12 (open histograms). D, Time kinetics showing IL-12-driven
up-regulation of granzyme B, but not perforin (mean values of six conditional killer clones; data are ratios of percentage of granzyme B (circles)- or perforin
(diamonds)-positive cells determined by intracellular staining after incubation with/without IL-12). E, PBMC from a representative healthy donor were
cultured similarly and stained with Abs specific for granzyme B (left) and perforin (right); histograms are from CD8CD3-gated cells after incubation
with IL-12 (filled histograms) and without IL-12 (open histograms). F, Time kinetics showing IL-12-driven up-regulation of granzyme B, but not perforin
(values are ratios of percentage of positive cells after incubation with/without IL-12; mean values from CD8CD3-gated cells from PBMC of four healthy
donors). Statistical comparisons of granzyme B expression with/without IL-12 are as follows: clones reached p  0.05 already at 24 h, CD8CD3 PBMC
only at 72 h (Student’s t test).
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with IL-2 (which we used for all T cell cultures), IL-12 signals
through an entirely distinct system involving different Jak/STAT
members and regulating different transcription factors and func-
tions (42–45), emphasizing that distinct molecular mechanisms
control T cell cytotoxicity. Bioavailability of IL-12 may be limited
to specialized cellular and microenvironmental compartments.
Mouse studies have shown that CD8-expressing dendritic cells
(DC) provide most of the IL-12 acting on CD8 T cells (38). Thus,
the availability of IL-12 is most likely limited to the vicinity of
activated DC in lymphoid tissues and inflammatory lesions. It may
well be that the strong toxicity seen in patients after systemic treat-
ment with IL-12 (46) is related to the capacity of IL-12 to induce
cytotoxicity.
Our finding of increased cytokine production, especially IL-2,
by CD28-positive T cells was not surprising, because T cells in
early and intermediate (CD28), but not late (CD28) differenti-
ation stages are known to produce IL-2 (47). Studies in mice have
directly confirmed that absence of CD28-mediated costimulation
impairs IL-2 production by virus-specific CD8 T cells (21, 48).
Topp et al. (47) demonstrated that restoration of CD28 expression
in CD28-negative CD8 human T cells reconstitutes Ag-induced
IL-2 production. Interestingly, IL-2 production depended on intra-
cellular signaling via CD28, and the loss of CD28 appeared to be
the only critical blockade to IL-2 production by CD28-negative
CD8 T cells. Triggering through other (costimulatory) molecules
such as CD2, CD27, 41BB, or LFA-1 was not essential for IL-2
production (47).
Absence of lytic function may suggest partial tolerance (41).
However, at least in mice, some nonlytic CD8 T cells have pro-
tective potential, for example, by IFN- secretion important for
CD8 T cell-mediated tumor defense (49) and protection against
some viruses (50, 51). There are further indications that CD28-
positive T cells play central protective roles. CD28 expression and
IL-2 production by CD8 T cells could be particularly critical in
diseases associated with poor CD4 helper cell responses, as for
example in HIV infection (52) and tumors (53). A recent study
demonstrated that IL-2 expression was a feature of subsets of HIV-
1-specific CD8 T cells, and that this property correlated with CD4
cell-independent proliferation of CD8 T cells (54). It has been
reported that IL-2 production was primarily confined to the
CCR7/CD45RA central memory population, whereas IFN-
production was more prominent among CCR7/CD45RA EM
cells (9, 13, 55). In our patients, we attempted to include the anal-
ysis of CCR7/CD45RA central memory cells, but did not suc-
ceed because the vast majority of activated Melan-A-specific cells
was CCR7/CD45RA and only a very small fraction expressed
low (borderline) levels of CCR7, which is a frequent observation
in tumor Ag-specific T cells. However, IL-2 is also produced by a
fraction of EM cells, as recently reported for HIV-1-specific CD8
T cells (54). In this study, we raised evidence for IL-2 production
by tumor Ag-specific EM cells, and show that they are character-
ized by the expression of CD28. Whether the latter is also true for
human virus-specific CD8 T cells remains to be determined.
Recent studies have demonstrated uncoupling of proliferative
and effector function (56–58). Human CD8 T cells that proliferate
in vivo are preferentially found in the IL-2-producing subsets (59,
60). It is conceivable that proliferation of Ag-specific CD8 T cells
is a feature of protective immune responses (9–11, 61). In agree-
ment with in vivo observations, in vitro proliferation is favored by
CD28 stimulation, and CD28-positive T cells may sometimes
grow better as compared with CD28-negative cells (22). Thus,
CD28 triggering may be a central element in robust CD8 T cell
responses, and may be critically missing in nonproductive T cell
activation. The fact that solid tumors are B7 negative may be key
to understand the usually poor protection mediated by T cells.
Conversely, those human tumors that are the most susceptible to
immunotherapy are B7 positive: striking therapeutic effects can be
observed in leukemia patients through the graft-vs-leukemia effect
(62), and possibly also in B cell lymphoma patients upon active
specific immunotherapy (63, 64). However, CD28-negative CD8 T
cells can also proliferate considerably, as we have observed for
melanoma Ag-specific T cells in vivo and for the CD28-negative
derived clones described in this work that proliferated almost as
efficiently as their CD28-positive counterparts (65). It is important
to further assess the still many open questions regarding, for ex-
ample, time intervals and signaling pathways promoting successful
T cell growth and function of the different subsets, and most im-
portantly, to identify correlates of protection.
Although increasingly applied, ex vivo phenotyping of T cells
with surface markers (such as CD45RA, CCR7, CD28, or CD27)
is insufficient for the characterization of T cells with precisely
defined differentiation and functional status. We used these mark-
ers to set an arbitrary grid for the classification and further char-
acterization of T cells. Clearly, a classification based on functional
properties would be preferable, but ex vivo assessment of T cell
function is often not possible, and functionally important mole-
cules are mostly intracellular, making it impossible to sort viable
cells for further investigation. In general, a better understanding of
the T cell system relies on a much more detailed characterization
of cellular and molecular components and mechanisms involved in
T cell responses. Cell surface markers are still a valuable tool,
provided that they are not overinterpreted, e.g., as decisive for
distinct immune functions. Despite several efforts, we have not
(yet) been able to identify a cell surface marker (combination)
specific for the newly identified conditional killer T cells, which
would facilitate a more rapid and systematic investigation, includ-
ing the cell sorting and further study of underlying mechanisms.
A puzzling finding is that T cell clones derived from presumably
naive (CCR7/CD45RA) T cells were more strongly cytotoxic
than EM28-derived clones. Thus, in vitro priming may favor dif-
ferentiation toward cytotoxic effector cells, a conclusion that is
compatible with several studies on in vitro primed CD8 T cells (13,
35, 66, 67). It will be useful to elucidate the responsible mecha-
nisms. One possible reason may be that in vitro priming usually
occurs through DC (providing IL-12), whereas in vitro stimulation
of in vivo primed cells may often happen by nonprofessional APCs
lacking IL-12 and unable to convert conditional killer cells to cy-
totoxic effector T cells. This view is compatible with an elegant
mouse study that applied artificial APCs and showed that naive,
but not memory CD8 T cells required IL-12 to acquire cytotoxic
function (38). Alternatively, the conditional killer phenotype may
be generated through other mechanisms that may occur in vivo (to
some cells), but not during in vitro priming.
In our study, we also addressed the question whether killer and
conditional killer T cells differed in their capacity to recognize Ag.
The fact that all clones were positive in Ag-mediated killing assays
and/or in Ag-triggered cytokine release assays demonstrated that
they were capable of, and depended on, recognizing Melan-A
peptide Ag specifically. In addition, nearly all of these clones
also recognized HLA-A2 melanoma cells naturally expressing
Melan-A (data not shown), suggesting that they could sense rela-
tively low levels of Ag. We also found that peptide concentrations
required for 50% maximal cytokine production were in a similar
range for EM28- and EM28-derived clones (data not shown).
Finally, we sequenced the TCRs (data not shown) of the clones to
investigate whether some EM28-derived clones may have iden-
tical TCRs to cytotoxic and EM28-derived clones, which was,
however, not the case.
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Despite that the three patients had quantitative differences in the
proportions of the studied T cell subsets, all three subsets were
clearly present in the three patients, with substantial percentages of
CD28-positive and CD28-negative cells, including EM28 condi-
tional killer cells. Thus, our data suggest that the studied T cell
subsets can regularly be found, at least for self/tumor Ag-specific
T cells after patient vaccination with peptide and CpG 7909, emul-
sified in IFA. More recently, we studied T cells from a new patient
(LAU 50) with a very strong spontaneous CD8 T cell response
specific for the tumor-Ag NY-ESO-1 (6% multimer of circu-
lating CD8 T cells!). Preliminary data indicate that the EM28
population of this patient also contained nonlytic cells expressing
low levels of granzyme B and perforin ex vivo and in vitro (data
not shown), suggesting that this occurs also in the absence of vac-
cination. Furthermore, we found such conditional killer T cells in
anatomical compartments other than peripheral blood (68), i.e., in
tumor-infiltrated lymph node cells. Nevertheless, due to the limited
number of patients studied, it is too early to draw firm conclusions
as to whether this new subset can be found frequently or whether
it only exists due to exceptional conditions (of T cell activation) of
some cancer patients.
Effector and memory T cells are heterogenous. It is important to
elucidate the roles of the different subsets, and to identify how they
are regulated. Some differentiation stages can hardly be induced in
vitro. Therefore, in vivo/ex vivo analyses remain the gold standard.
However, experimental approaches are limited in humans. A way
to overcome such limitations is offered by the finding that selected
T cell functions are robustly imprinted in vivo, to the extent that
they are maintained in vitro over several months. Thus, specifically
isolated T cell clones can serve as reliable models, if built on
evidence as provided in this study, that the studied properties are
similar in vivo.
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